|Articles|March 19, 2020
Episode 52: Cannabinoids
Author(s)Christen Harm, Elaine Quilici
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Advertisement
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
2
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
3
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5